Zobrazeno 1 - 10
of 46
pro vyhledávání: '"O. C. Leeksma"'
Autor:
O. C. Leeksma, J. C. Giltay, J. Zandbergen-Spaargaren, P. W. Modderman, J. A. Van Mourik, A. E. G. Kr. von dem Borne
Publikováno v:
British Journal of Haematology. 66:369-373
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a4c42d43723255df041b0fde0804d13
https://doi.org/10.1111/j.1365-2141.1987.00355.x-i1
https://doi.org/10.1111/j.1365-2141.1987.00355.x-i1
Publikováno v:
British Journal of Haematology. 55:509-522
Summary. Two murine monoclonal antibodies specific for human platelets were prepared and characterized by immunofluorescence, immunoprecipitation and by studying their effect on platelet function. Immunoprecipitation with lysates of normal platelets
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77f9f13cb6151570f81b31cb80b052dc
https://doi.org/10.1111/j.1365-2141.1983.00509.x
https://doi.org/10.1111/j.1365-2141.1983.00509.x
Publikováno v:
Biochemical Journal. 387:627-637
TESK1 (testicular protein kinase 1) is a serine/threonine kinase that phosphorylates cofilin and plays a critical role in integrin-mediated actin cytoskeletal reorganization and cell spreading. We previously showed that TESK1 interacts with Sprouty-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c71d48577e2869bc8a6328028f250e03
https://doi.org/10.1042/bj20041181
https://doi.org/10.1042/bj20041181
Autor:
Marcel Spaargaren, Carlie J.M. de Vries, Tanja A. E. van Achterberg, O. C. Leeksma, Clemens Mellink, Hans Pannekoek, Eric Eldering, Yoshikazu Tsumura, Kensaku Mizuno, Wilma G. M. Kroes, Jiro Toshima
Publikováno v:
European Journal of Biochemistry. 269:2546-2556
The Drosophila melanogaster protein sprouty is induced upon fibroblast growth factor (FGF)- and epidermal growth factor (EGF)-receptor tyrosine kinase activation and acts as an inhibitor of the ras/MAP kinase pathway downstream of these receptors. By
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e7e324b82667688a183cb28fbfba242
https://doi.org/10.1046/j.1432-1033.2002.02921.x
https://doi.org/10.1046/j.1432-1033.2002.02921.x
Publikováno v:
Blood Cancer Journal. 7:e541-e541
Correction to: Blood Cancer Journal (2017) 7, e532; doi:/doifinder/10.1038/bcj.2017.15; published online 17 February 2017 Following the online publication of this article, the author noticed an error in Table 1. Reference 3030 should be 29 as both LI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62e1547b897d5a2780449fcfff8fe44c
https://doi.org/10.1038/bcj.2017.22
https://doi.org/10.1038/bcj.2017.22
Autor:
O. C. Leeksma, Rafael Hurtado Monroy, Stefania Miglietta, Philipp le Coutre, Fabrizio Pane, Muheez A. Durosinmi, Arnon Nagler, François Guilhot, Carlo Gambacorti-Passerini, Josy Reiffers, Laura Antolini, Giuseppe Saglio, Enrica Morra, Maria Grazia Valsecchi, Il-Young Kweon, Dong-Wook Kim, Francesco Di Raimondo, Alessandro Rambaldi, Michael W. Deininger, Elisabetta Abruzzese, Francois-Xavier Mahon
Abstract 2199 Poster Board II-176 Imatinib is an effective first line therapy for chronic myeloid leukemia (CML) and has substantially changed its biological and clinical behavior. Durable complete cytogenetic responses (CCyR) were reported in the ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05802c095b75b58f35cca7d8abe0e5ea
http://hdl.handle.net/20.500.11769/81537
http://hdl.handle.net/20.500.11769/81537
Autor:
Marcel Camps, C. J. M. Melief, Ferry Ossendorp, R. Offringa, O C Leeksma, A. de Ru, Jan W. Drijfhout, Jan H. Kessler, Sandra A. Bres-Vloemans, P.A. van Veelen, Arnout Mulder, I J G Huijbers
Publikováno v:
Leukemia. 20(10)
For immunotherapy of residual disease in patients with Philadelphia-positive leukemias, the BCR-ABL fusion regions are attractive disease-specific T-cell targets. We analyzed these regions for the prevalence of cytotoxic T lymphocyte (CTL) epitopes b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66bb67c42b58e625a6ebabb2cb0b706c
https://pubmed.ncbi.nlm.nih.gov/16932347
https://pubmed.ncbi.nlm.nih.gov/16932347
Autor:
G J, ten Bosch, J H, Kessler, A M, Joosten, A A, Bres-Vloemans, A, Geluk, B C, Godthelp, J, van Bergen, C J, Melief, O C, Leeksma
Publikováno v:
Blood. 94(3)
Peptides corresponding to the fusion site in 210 kD BCR-ABL protein b3a2 (p210b3a2) were previously shown to bind to several HLA class I and II alleles. We have found that b3a2 peptide-specific CD4-positive T-helper cells were able to recognize p210b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9c91804846b6e9298fc72c73852852c8
https://pubmed.ncbi.nlm.nih.gov/10419896
https://pubmed.ncbi.nlm.nih.gov/10419896
Autor:
G J, ten Bosch, J H, Kessler, J, Blom, A M, Joosten, C, Gambacorti-Passerini, C J, Melief, O C, Leeksma
Publikováno v:
British journal of haematology. 103(4)
Constitutive tyrosine phosphorylation of CrkL was recently demonstrated in platelets from chronic myelogenous leukaemia (CML) patients but BCR-ABL tyrosine kinase could not be detected in the platelet lysates. We studied platelets from 14 CML patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d43d9956ecc036038f2b15274b20d4c0
https://pubmed.ncbi.nlm.nih.gov/9886328
https://pubmed.ncbi.nlm.nih.gov/9886328
Publikováno v:
Blood. 88(9)
In chronic myeloid leukemia (CML) the classical 9;22 translocation results in a BCR-ABL fusion gene, which encodes chimeric BCR-ABL fusion 210 kD oncoproteins (p210BCR-ABL). The two main p210BCR-ABL fusion variants in CML, b2a2 and b3a2 are examples
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::56a93b3aa1fc8adeddb9b273550e8368
https://pubmed.ncbi.nlm.nih.gov/8896419
https://pubmed.ncbi.nlm.nih.gov/8896419